Autopsy report · NCT03603964

Guadecitabine Extension Study

“Early termination not due to patient safety”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 3 months before it stopped.
• 35 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Astex Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Acute Myeloid Leukemia; Myeloid Dysplastic Syndrome

Interventions

Guadecitabine

Participants

35

Sites

21

Countries

Austria, Canada, Denmark, Italy, Japan, South Korea, Spain, Taiwan, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.